Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(2s,3s)-trans‑2,3‑dihydro‑3‑hydroxyanthranilic acid is a small molecule and a chiral cyclic β-amino acid derivative with the molecular formula C7H9NO3 and a molecular weight of 155.15 g/mol[1][2][5]. It features both hydroxyl and amino functional groups on a cyclohexene ring. This compound is primarily studied as an experimental research chemical rather than as an approved pharmaceutical agent[1][5]. Its biological activity includes antioxidant and anti-inflammatory properties; it can modulate oxidative stress by reducing reactive oxygen species in cells and may influence inflammatory pathways[6]. The compound has also been investigated for its potential anticancer effects due to its ability to inhibit cancer cell proliferation in preliminary studies[6]. Mechanistically, it interacts with various enzymes—potentially acting as either inhibitor or activator depending on context—and binds target proteins via its hydroxyl group and chiral centers[6]. It is not currently approved for any medical indication but has been used in biochemical research related to enzyme function and metabolic pathway studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2s,3s)-trans-2,3-dihydro-3-hydroxyanthranilic acid.